

CLINIMIX
(amino acids in dextrose) Injections

CLINIMIX E
(amino acids with electrolytes in dextrose
with calcium) Injections

CLINIMIX and CLINIMIX E Injections

Nutrient Profile

INDICATIONS

CLINIMIX (amino acids in dextrose) Injections and CLINIMIX E (amino acids with electrolytes in dextrose with calcium) Injections are indicated as a source of calories and protein (and electrolytes for CLINIMIX E) for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX and CLINIMIX E may be used to treat negative nitrogen balance in patients.

Please see Indications and Important Risk Information on inside page

Please see accompanying Package Inserts for full Prescribing Information



Baxter

CLINIMIX [amino acids in dextrose] and CLINIMIX E

Nutrients per 1-Liter Container

1 liter	PRODUCT	CLINIMIX Inj. 2B7726
		4.25/5
Final concentrations AFTER mixing.	Total Volume (without lipids)	1-Liter
	Amino Acid Concentration	4.25%
	Dextrose Concentration	5%
	gm Dextrose/L	50
	gm Amino Acids/L	42.5
	gm Nitrogen/L	7.02
	Sodium (mEq/L)	–
	Potassium (mEq/L)	–
	Magnesium (mEq/L)	–
	Calcium (mEq/L)	–
	Acetate (mEq/L)	37
	Chloride (mEq/L)	17
	Phosphate (as $\text{HPO}_4^{=}$) (mmol/L)	–
pH*	6.0	
Osmolarity (mOsmol/L)	675	
Kcal from Amino Acids/L	170	
Kcal from Dextrose/L	170	
Total Kcal/L	340	
	Total Kcal with IV Fat Emulsion added**	
+	20% 500 mL (1000 Kcal)	1340
+	20% 250 mL (500 Kcal)	840
+	10% 500 mL (550 Kcal)	890
+	10% 250 mL (275 Kcal)	615

* pH Range = 4.5-7.0 ** Data on file, Baxter Healthcare Corporation.

amino acids with electrolytes in dextrose with calcium] Inje

CLINIMIX Inj. 2B7727 4.25/10	CLINIMIX Inj. 2B7730 5/15	CLINIMIX Inj. 2B7731 5/20	CLINIMIX E Inj. 2B7735 2.75/5
1-Liter	1-Liter	1-Liter	1-Liter
4.25%	5%	5%	2.75%
10%	15%	20%	5%
100	150	200	50
42.5	50	50	27.5
7.02	8.26	8.26	4.54
--	--	--	35
--	--	--	30
--	--	--	5
--	--	--	4.5
37	42	42	51
17	20	20	39
--	--	--	15
6.0	6.0	6.0	6.0
930	1255	1505	665
170	200	200	110
340	510	680	170
510	710	880	280
1510	1710	1880	1280
1010	1210	1380	780
1060	1260	1430	830
785	985	1155	555

Please see accompanying Package Inserts for full Prescribing Information

Sections Nutritional Profile

CLINIMIX E Inj. 2B7737 4.25/5	CLINIMIX E Inj. 2B7738 4.25/10	CLINIMIX E Inj. 2B7740 5/15	CLINIMIX E Inj. 2B7741 5/20
1-Liter	1-Liter	1-Liter	1-Liter
4.25%	4.25%	5%	5%
5%	10%	15%	20%
50	100	150	200
42.5	42.5	50	50
7.02	7.02	8.26	8.26
35	35	35	35
30	30	30	30
5	5	5	5
4.5	4.5	4.5	4.5
70	70	80	80
39	39	39	39
15	15	15	15
6.0	6.0	6.0	6.0
815	1070	1395	1650
170	170	200	200
170	340	510	680
340	510	710	880
1340	1510	1710	1880
840	1010	1210	1380
890	1060	1260	1430
615	785	985	1155

Nutrients per 2-Liter Container

2

PRODUCT

liter

	Total Volume (without lipids)
Final concentrations AFTER mixing.	Amino Acid Concentration
	Dextrose Concentration
	gm Dextrose/2 L
	gm Amino Acids/2 L
	gm Nitrogen/2 L
	Sodium (mEq/2 L)
	Potassium (mEq/2 L)
	Magnesium (mEq/2 L)
	Calcium (mEq/2 L)
	Acetate (mEq/2 L)
	Chloride (mEq/2 L)
	Phosphate (as HPO_4^{2-}) (mmol/2 L)
	pH*
	Osmolarity (mOsmol/L)
	Kcal from Amino Acids/2 L
	Kcal from Dextrose/2 L
	Total Kcal/2 L
	Total Kcal with IV Fat Emulsion added**
+	20% 500 mL (1000 Kcal)
+	20% 250 mL (500 Kcal)
+	10% 500 mL (550 Kcal)
+	10% 250 mL (275 Kcal)

E amino acids with electrolytes in dextrose with calcium] Inj

CLINIMIX Inj. 2B7704 4.25/5	CLINIMIX Inj. 2B7705 4.25/10	CLINIMIX Inj. 2B7709 5/15	CLINIMIX Inj. 2B7710 5/20
2-Liter	2-Liter	2-Liter	2-Liter
4.25%	4.25%	5%	5%
5%	10%	15%	20%
100	200	300	400
85	85	100	100
14.04	14.04	16.52	16.52
--	--	--	--
--	--	--	--
--	--	--	--
--	--	--	--
74	74	84	84
34	34	40	40
--	--	--	--
6.0	6.0	6.0	6.0
675	930	1255	1505
340	340	400	400
340	680	1020	1360
680	1020	1420	1760
1680	2020	2420	2760
1180	1520	1920	2260
1230	1570	1970	2310
955	1295	1695	2035

Please see accompanying Package Inserts for full Prescribing Information

lections Nutritional Profile

CLINIMIX E Inj. 2B7716 4.25/5	CLINIMIX E Inj. 2B7717 4.25/10	CLINIMIX E Inj. 2B7721 5/15	CLINIMIX E Inj. 2B7722 5/20
2-Liter	2-Liter	2-Liter	2-Liter
4.25%	4.25%	5%	5%
5%	10%	15%	20%
100	200	300	400
85	85	100	100
14.04	14.04	16.52	16.52
70	70	70	70
60	60	60	60
10	10	10	10
9	9	9	9
140	140	160	160
78	78	78	78
30	30	30	30
6.0	6.0	6.0	6.0
815	1070	1395	1650
340	340	400	400
340	680	1020	1360
680	1020	1420	1760
1680	2020	2420	2760
1180	1520	1920	2260
1230	1570	1970	2310
955	1295	1695	2035

To mix solutions

- 1 Grasp the container firmly on each side of the top of the bag (hanger end).
- 2 Roll the bag to open seal between chambers as shown.
- 3 Mix solutions thoroughly.
- 4 Check for leaks.

SELECTED IMPORTANT RISK INFORMATION

CLINIMIX and CLINIMIX E Injections are contraindicated in patients with known hypersensitivity to one or more amino acids or dextrose; in patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications; and in patients with pulmonary edema or acidosis due to low cardiac output. In addition, CLINIMIX E is contraindicated in neonates (less than 28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate's bloodstream.



With Vertical Peel Seal CLARITY Dual Chamber Container in 1 L and 2 L sizes

INDICATIONS

CLINIMIX (amino acids in dextrose) Injections and CLINIMIX E (amino acids with electrolytes in dextrose with calcium) Injections are indicated as a source of calories and protein (and electrolytes for CLINIMIX E) for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX and CLINIMIX E may be used to treat negative nitrogen balance in patients.

IMPORTANT RISK INFORMATION

- CLINIMIX and CLINIMIX E Injections are contraindicated in patients with known hypersensitivity to one or more amino acids or dextrose; in patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications; and in patients with pulmonary edema or acidosis due to low cardiac output. In addition, CLINIMIX E is contraindicated in neonates (less than 28 days of age) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate's bloodstream.
- Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. The solution should be inspected for precipitates before admixing, after admixing, and again before administration. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.
- Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with CLINIMIX E, in the same intravenous administration line. Do not administer ceftriaxone simultaneously with CLINIMIX E via a Y-site.
- Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop.
- Monitor for signs and symptoms of early infections.
- Refeeding severely undernourished patients may result in refeeding syndrome. Thiamine deficiency and fluid retention may also develop. Monitor severely undernourished patients and slowly increase nutrient intakes.

- CLINIMIX and CLINIMIX E solutions containing more than 5% dextrose have an osmolarity of ≥ 900 mOsm/L and must be infused through a central catheter.
- CLINIMIX and CLINIMIX E contain no more than 25 mcg/L of aluminum which may reach toxic levels with prolonged administration in patients with renal impairment. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum. Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
- Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants. If CLINIMIX and CLINIMIX E treated patients develop liver test abnormalities consider discontinuation or dosage reduction.
- Use CLINIMIX and CLINIMIX E with caution in patients with cardiac insufficiency or renal impairment due to increased risk of electrolyte and fluid volume imbalance.
- Monitor renal and liver function parameters, ammonia levels, fluid and electrolyte status, serum osmolarity, blood glucose, blood count and coagulation parameters throughout treatment. In situations of severely elevated electrolyte levels, stop CLINIMIX and CLINIMIX E until levels have been corrected.
- Adverse reactions include diuresis, extravasation, glycosuria, hyperglycemia, and hyperosmolar coma.

Please see accompanying Package Inserts for full Prescribing Information

For more information,
contact Medical Information at
1-800-422-2751 or visit
www.baxtermedicationdeliveryproducts.com


CLINIMIX
(amino acids in dextrose) Injections


CLINIMIX E
(amino acids with electrolytes in dextrose
with calcium) Injections

Please see Indications and Important Risk Information on inside page
Please see accompanying Package Inserts for full Prescribing Information

www.baxter.com

Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015

Baxter, Clarity, Clinimix, Clinimix E, the Clinimix logo are trademarks of
Baxter International Inc.

USMP/78/14-0004(2) 5/18

Baxter